AuroLase® Therapy is investigational at this current time and only available through designated FDA sanctioned clinical study sites. Patients must be enrolled by the participating physician at that clinical study site and must meet the enrollment criteria based on the physician's evaluation. 

Current Clinical Study- Recurrent or Refractory Head and Neck Cancer

Under FDA guidelines, we have received authorization for and began a human study in 2008 for the treatment of refractory or recurrent head and neck cancers with very specific patient criteria. The therapy is not available for other cancers or any hospitals other than the designated clinical study sites.

Not all head and neck cancer patients will qualify for the study. A brief summary of certain of the eligibility criteria are:

• Patients must have documented histological or cytological evidence of tumor(s) of the head and neck
• Patients must be > 18 years of age
• Patients must have ECOG Performance Score of 0, 1 or 2
• Patients or their legal representative must be able to read, understand and sign an informed consent
• Patients must meet minimum health requirements for renal and hepatic function
• Patient must not have had chemotherapy, radiation or other treatments within 30 days of the AuroLase® Therapy procedure

Other cancer applications are under development. Updates regarding future clinical trials will be posted as they become available.

For More Information

For more information regarding basic research, clinical studies,
or other topics, please contact J. Donald Payne
at DPayne@Nanospectra.com.